Karve Sudeep J, Feldman Steven R, Yentzer Brad A, Pearce Daniel J, Balkrishnan Rajesh
Department of Pharmacy Practice and Administration, The Ohio State University College of Pharmacy, Columbus, OH 43210, USA.
J Drugs Dermatol. 2008 Nov;7(11):1044-51.
Basal cell carcinoma (BCC) is regarded as the most prevalent malignant skin tumor in whites. A variety of surgical and nonsurgical interventions are available to treat BCC. In recent years, an immune response modifier drug, imiquimod, has been approved in treating superficial BCC (sBCC). The objective of the authors was to review the published literature to evaluate outcomes such as efficacy, safety, and quality of life associated with imiquimod treatment among patients with sBCC. A MEDLINE search of the literature was performed to identify studies published between January 1, 1995 and March 31, 2008 that evaluated imiquimod efficacy, safety, and quality of life in treating BCC. Overall, imiquimod 5% cream was associated with increased clinical and histologic clearance among patients with sBCC as compared to placebo. The findings from short-term cost effectiveness studies suggest that use of imiquimod 5% cream can be more cost-effective than surgical interventions such as excision surgery among patients with superficial BCC. Future studies evaluating long term cost effectiveness of imiquimod treatment are warranted.
基底细胞癌（BCC）被认为是白种人中最常见的恶性皮肤肿瘤。有多种手术和非手术干预方法可用于治疗BCC。近年来，一种免疫反应调节剂药物咪喹莫特已被批准用于治疗浅表性BCC（sBCC）。作者的目的是回顾已发表的文献，以评估sBCC患者使用咪喹莫特治疗的疗效、安全性和生活质量等结果。对MEDLINE数据库进行文献检索，以确定1995年1月1日至2008年3月31日期间发表的评估咪喹莫特治疗BCC的疗效、安全性和生活质量的研究。总体而言，与安慰剂相比，5%咪喹莫特乳膏使sBCC患者的临床和组织学清除率提高。短期成本效益研究的结果表明，对于浅表性BCC患者，使用5%咪喹莫特乳膏可能比手术切除等手术干预更具成本效益。有必要开展未来研究评估咪喹莫特治疗的长期成本效益。
